Adagene Completes Phase 2 Enrollment, Triggering $8M Sanofi Second Closing
ADAG sits 54% above its 52-week low of $1.3.
Summary
Adagene completed enrollment of 60 patients in its randomized Phase 2 muzastotug/KEYTRUDA trial in MSS colorectal cancer, satisfying the milestone for Sanofi's US$8.0 million second closing around November 20, 2026 and bringing Sanofi's total investment to US$25.0 million. Initial dose-optimization results are expected in 1H 2027 to set the Phase 3 regimen.
Key Events · M&A and Partnerships · ADAG
-
Phase 2 Enrollment Complete
All 60 patients have been enrolled and randomized 1:1 across two muzastotug dosing arms combined with pembrolizumab in late-line MSS colorectal cancer without liver metastases.
-
Sanofi Second Closing Triggered
The enrollment milestone satisfies the condition for Sanofi's US$8.0 million second closing, expected on or around November 20, 2026, via 378,788 additional Series A Preferred Shares.
-
Total Sanofi Commitment $25M
Combined with the US$17.0 million first closing on July 2, 2025 (1,062,500 preferred shares), Sanofi's total investment under the June 30, 2025 securities purchase agreement reaches US$25.0 million.
-
Dose Data Due 1H 2027
Initial results from the randomized dose-optimization trial are expected in the first half of 2027 and will inform the dose regimen for the Phase 3 registration trial.
Analysis · ADAG · Life Sciences
The contractual milestone for Sanofi's second tranche has been met: Adagene finished enrolling all 60 patients in the randomized Phase 2 dose-optimization trial of muzastotug plus KEYTRUDA in late-line MSS colorectal cancer. That unlocks US$8.0 million on or around November 20, 2026 and lifts Sanofi's total commitment to US$25.0 million — non-dilutive-to-cash runway support at a company that reported US$127.9M in cash in August. The trade-off is dilution: 378,788 Series A Preferred Shares convert into roughly 3.79 million ordinary shares, against 1,062,500 preferred issued in the July 2025 first closing. The real value driver is the readout: initial dose-optimization data in 1H 2027 will pick the regimen for the Phase 3 registration trial, where the FDA has already agreed on an OS primary endpoint and a standard-of-care control arm without a monotherapy arm.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADAG was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $161.8M. The 52-week trading range was $1.30 to $4.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.